Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Chemotherapy and Surgery in Recurrent Ovarian, Peritoneal Primary, and Fallopian Tube Cancer
NCT00565851Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2007
- Primary completion
- Apr 2019
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of bevacizumab in ovarian cancer, primary peritoneal carcinoma (PPC), fallopian tube cancer (PFTC), sponsored by National Cancer Institute. Started Dec 2007; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00565851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00565851.